CJC-1295 Side Effects: What Is Documented and What Is Not

CJC-1295 has more paper trail than most research peptides, and most of it is not the flattering kind. A real Phase 1 human trial exists. So does a Phase 2 trial that was stopped after a participant died. So does a 2024 FDA advisory committee review that spent a session on it by name. That is unusual for this category, where "side effects" pages are normally built entirely from forum reports and vendor blog posts, and it means this page can be more specific than most about what is and is not known.

Everything below is research use information. It is not medical advice, and none of it substitutes for supervision by a qualified clinician who can see your bloodwork and your history.

DAC and No-DAC Are Different Exposures

Before the safety data, one distinction matters more here than on most compound pages. CJC-1295 without DAC, also called Modified GRF (1-29), clears in minutes and is dosed daily in micrograms to mimic a natural GHRH pulse. CJC-1295 with DAC binds to albumin, which extends its half life from minutes to days, and is dosed weekly in milligrams. The CJC-1295 dosage guide covers the arithmetic for both. Every side effect below that depends on how long growth hormone and IGF-1 stay elevated will, in principle, run longer on the DAC version than the no-DAC version, because that is the entire point of DAC. No study has directly compared the two for safety; that is inference from mechanism, not a tested finding.

The Phase 1 Human Data

The only published controlled human dosing study is from 2006: two randomized, double-blind, placebo-controlled ascending-dose trials, running 28 and 49 days, in healthy adults aged 21 to 61. The first trial gave one of four ascending single subcutaneous doses, the second gave two or three doses a week or two apart, each against placebo. After a single injection, growth hormone rose 2 to 10-fold depending on dose and stayed up for six days or more, and the estimated half life was 5.8 to 8.1 days. IGF-1 rose 1.5 to 3-fold and, notably, stayed elevated for 9 to 11 days after a single injection, which is the data point behind the DAC dosing interval used today.

The published abstract for this trial describes it as a safety and pharmacokinetic study and reports no serious adverse reactions, and the authors describe it as relatively well tolerated, particularly at 30 or 60 micrograms per kilogram. Detailed adverse event tables from that trial are not available in the public abstract, so a specific rate for injection site reactions, headache or flushing from this trial cannot be quoted honestly. What can be said is that this is the one dataset in the CJC-1295 record that meets a normal bar for human trial evidence, and it found the hormonal effect worked broadly as intended without a reported serious event, in a healthy adult population, over 28 to 49 days.

Injection Site Reactions and Commonly Reported Effects

Outside the Phase 1 trial, most of what circulates about CJC-1295 side effects comes from peptide clinic and vendor marketing pages rather than controlled studies, and it should be read at that level of confidence. The pattern that recurs across those sources, and that follows from the compound's mechanism, includes injection site pain, swelling or induration that typically resolves within a day or two, transient facial or upper body flushing shortly after a dose, headache, lightheadedness, and the water retention and joint fullness that show up with most growth hormone secretagogues. None of this is independently verified the way the Phase 1 trial's topline results are, and no source has published a rate for how often any of it occurs.

The mechanism gives a reasonable framework for interpreting it anyway. CJC-1295 is a GHRH analog, not an unselective secretagogue, so it works upstream of the pituitary's own feedback loop rather than around it, which is the same reasoning covered in the sermorelin side effects page for that related compound. Fluid retention and joint symptoms would be expected to track how strongly an individual's growth hormone axis responds, and to be more noticeable at the higher end of a dosing range, rather than being fixed per milligram.

The 2006 Phase 2 Trial and the Participant Death

This is the part of the CJC-1295 record most vendor pages leave out, and it is the reason the FDA's later review treats the compound cautiously. In the same year as the Phase 1 trial, a separate Phase 2 study tested CJC-1295 in 192 participants with HIV-related visceral fat accumulation, a multicentre, randomised, placebo-controlled, double-blind trial run across sites in North and South America.

Two things are true at once here, and a fair page has to hold both. The physician's contemporaneous read was that the death was unrelated to the drug, in a patient with a plausible pre-existing cause. And the program stopped anyway, and nearly two decades later a federal regulator still described the question as open rather than settled. Neither of those facts should be dropped to make the other one sound more definitive than the record actually supports.

The FDA's 2023 to 2024 Review

CJC-1295 has never been an FDA-approved drug. In 2023, the FDA placed it in Category 2 of the interim list of bulk drug substances nominated for pharmacy compounding under section 503A, the category reserved for substances with significant identified safety concerns. The concerns named were nonclinical toxicity findings, specifically DNA damage observed in pituitary cells and injection-site necrosis in animal studies, the unresolved cardiac signal from the 2006 Phase 2 trial above, and immunogenicity risk.

The formal nomination to add CJC-1295 to the permanent 503A bulks list was withdrawn by its nominator, and the FDA removed it from Category 2 as of September 27, 2024. On December 4, 2024, the FDA's Pharmacy Compounding Advisory Committee voted in agreement with the agency's recommendation against including CJC-1295 on the final 503A list. The practical result is that CJC-1295 currently sits outside the pharmacy compounding system entirely: not on the 503A list, not on the 503B list, no USP or NF monograph, and not a component of any approved drug product. That is a regulatory vacancy, not a clean bill of health and not a ban.

Who Should Not Use It, and Why Supervision Matters

Given the unresolved cardiac question from the 2006 trial, anyone with known or suspected cardiovascular disease has a specific, named reason for caution here that goes beyond the generic advice on other GHRH analog pages. Active or recent malignancy is a clear stop, since IGF-1 is a growth signal. Pregnancy and breastfeeding have no safety data at all. Untreated thyroid or adrenal dysfunction means the growth hormone axis is not behaving normally to begin with, and anyone on medications touching the endocrine system belongs in a clinician's office rather than a forum thread.

There is also the supply chain risk that applies across this entire category. CJC-1295 sold as a research chemical carries no assurance of identity, purity or sterility, and the FDA's nonclinical toxicity concerns above were about the molecule itself in controlled animal studies, not about what a mislabelled or contaminated vial could add on top of that. The general peptide side effects page covers why supply quality is frequently the larger variable in this market.

What This Page Cannot Tell You

There is no multi-year controlled follow-up of CJC-1295 in adults using it for body composition, sleep or general wellbeing, DAC or no-DAC. The Phase 1 trial ran 28 to 49 days in healthy adults. The Phase 2 trial that would have generated a longer, larger safety record in a different population did not finish. Long term CJC-1295 side effects are unknown, not absent, and anyone presenting a confident long term safety claim in either direction is filling a real gap in the record rather than reporting a finding from it. The CJC-1295 and ipamorelin stack page covers what is and is not known about combining it with a GHRP, which adds its own effects on top of an already incomplete picture.

Frequently Asked Questions

Is CJC-1295 safe?

There is no clean answer. The only controlled human dosing data is a 2006 Phase 1 trial in healthy adults that reported no serious adverse events at the doses tested, but a separate Phase 2 trial in a sicker population was halted the same year after a participant died, and the FDA's 2023 to 2024 review cited nonclinical toxicity findings and called the cardiac signal from that trial unresolved. CJC-1295 has never been an approved drug and is not on the FDA's compounding bulks list. Anyone using it is working with genuinely limited safety data, not an established profile.

Did someone die in a CJC-1295 clinical trial?

Yes, in a related but separate study. A 2006 Phase 2 trial of CJC-1295 in 192 people with HIV-related visceral obesity was halted after a participant in Argentina died following the 11th weekly dose, from a confirmed heart attack roughly three hours after injection. The attending physician's assessment was pre-existing coronary artery disease, judged unrelated to the drug, but the sponsor stopped the program as a precaution. The FDA later described the cardiac question from that trial as unresolved rather than closed.

What did the CJC-1295 human trial actually find?

The only published human safety and dosing data is a 2006 Phase 1 program, two ascending-dose trials over 28 and 49 days in healthy adults aged 21 to 61. Four ascending single doses were tested, then repeat doses a week or two apart. Growth hormone rose 2 to 10-fold depending on dose, and IGF-1 stayed elevated for 9 to 11 days after a single injection. The published results describe this as a Phase 1 safety and dosing study; detailed adverse event tables are not available from the public abstract.

Is CJC-1295 with DAC more dangerous than without DAC?

Nobody has published a head to head comparison, so this is inference from mechanism, not data. DAC binds the peptide to albumin and extends its half life from minutes to days, which is why a single DAC dose keeps IGF-1 elevated for over a week in the 2006 trial. Any effect tied to sustained IGF-1 exposure would logically run longer on DAC than on the no-DAC version, which clears in minutes and is dosed more like a short pulse. That is a reasonable inference, not a tested finding.

Is CJC-1295 legal or FDA approved?

It has never been an FDA-approved drug and is not a component of one. In 2023 the FDA placed it in Category 2 of the interim 503A compounding bulks list, meaning it identified safety concerns significant enough to block traditional pharmacy compounding. The nomination to formally add it to that list was withdrawn in September 2024, and the FDA's advisory committee voted in December 2024 against including it. CJC-1295 currently sits outside the compounding system entirely: not on 503A, not on 503B, no USP or NF monograph.